XML 58 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
Asset Acquisition (Details) - Xinvento B.V. - USD ($)
$ in Thousands
12 Months Ended
Feb. 27, 2023
Dec. 31, 2023
Mar. 31, 2024
Asset Acquisition      
Aggregate Payment Upon Achievement Of Development And Commercial Milestones $ 206,000    
Clinical development milestone payments 6,000    
Regulatory approval and commercial milestones milestone payments 125,000    
Sales milestone payments 75,000    
Purchase consideration 5,667    
Cash consideration 4,520    
Holdback, payable on the one-year anniversary of the acquisition     $ 500
Acquisition related costs $ 647    
Research and development      
Asset Acquisition      
Purchase consideration   $ 5,667